News

A number of important discoveries, therapeutic developments, and events related to multiple sclerosis (MS) were reported daily by Multiple Sclerosis News Today throughout 2016. Now that the year is over, it is time to briefly review the articles that appealed most to our readers. Here are the top 10 most-read articles of 2016, with…

Lack of physical activity and a poor diet may be the most common risk factors for poor health and survival in patients with multiple sclerosis (MS), according to a study. The research, “Individual And Co-Occurring SNAP Risk Factors,” was published in the International Journal of MS Care. The development…

Recently published data from three Phase 3 trials of Ocrevus (ocrelizumab) show that the investigational drug does what no other therapy has achieved so far — working to prevent disease in both relapsing and primary progressive (PP) forms of multiple sclerosis (MS). Publications in the New England Journal…

Ibudilast (MN-166) has shown enough promise as a treatment for progressive multiple sclerosis (MS) that its U.S. Phase 2b trial (NCT01982942) should continue, the U.S. National Institute of Health’s Data and Safety Monitoring Board has recommended. A key goal of the 96-week trial is to determine whether ibudilast can slow the…

President Obama’s signing of the 21st Century Cures Act on Dec. 13 is expected to bring real change to those living with multiple sclerosis (MS). The legislation will lead to better research and clinical trials. It also puts increased weight on the role patients play in developing treatments for their…

The 21st Century Cures Act, recently signed into law by President Barack Obama, includes provisions that aim to speed up the process by which the U.S. Food and Drug Administration (FDA) reviews stem cell treatments for patients with degenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and Parkinson’s disease. This act also…

The U.S. Food and Drug Administration recently extended until the end of March its review of the Biologics License Application (BLA) for Ocrevus (ocrelizumab). The application was submitted by Roche, requesting FDA approval for Ocrevus as a treatment for patients with relapsing-remitting multiple sclerosis (RRMS) and — for a first…

Genentech is recruiting U.S. participants for a Phase 3 study (NCT02637856) of Ocrevus (ocrelizumab) in people with relapsing-remitting multiple sclerosis (RRMS) who were not helped by previous disease-modifying therapies, according to a press release from the National Multiple Sclerosis Society. The trial is an open-label study, meaning…

The discovery of a new type of immune cell in the membranes covering the brain is likely to advance understanding of the immune system’s impact on the brain, a study says. It could also lead to new treatments for multiple sclerosis (MS) and other neurodegenerative diseases. Researchers knew the immune…

Ari Waisman, a multiple sclerosis (MS) researcher credited with having made major contributions to “the successful development of modern anti-inflammatory and immunomodulatory therapies,” was recently honored by the Sobek Foundation. The author of over 170 scientific articles on MS, Waisman is the director of the Institute for Molecular Medicine at the University Medical Center…

Researchers, using camels as an inspiration, have finally developed antibodies against a group of proteins known as metalloproteinases (MMPs), which are involved in the pathology of diseases that include multiple sclerosis (MS) and cancer. Results on this work, long a goal of scientists, were published in the journal PNAS, under…

Nine research teams at the University of Virginia and Virginia Tech will be awarded grants totaling $550,000 for studies addressing issues related to brain development and brain function in health and disease. Among the university-funded projects receiving between $50,000 and $70,000 each is research into potential new treatments for multiple sclerosis. “We are planting seeds that…

Scientists at the University of Buffalo have identified a critical step in the process of nerve myelination after birth, a discovery that holds promise for the development of more effective therapies for neurodegenerative diseases like multiple sclerosis (MS). The research involved the study of voltage-operated calcium channels, which initiate many physiological…

The U.S. Food and Drug Administration (FDA) has accepted Bayer’s filing of a supplemental biologics license application (sBLA) for two products designed to improve the lives of people with multiple sclerosis (MS): myBETAapp and the BETACONNECT Navigator. Bayer created the BETACONNECT system to increase patient treatment compliance and improve…

Hemoglobin leaking from injured red blood cells may be associated with brain atrophy in secondary progressive multiple sclerosis (SPMS), according to researchers at the Imperial College London, U.K. The study, “Free Serum Haemoglobin Is Associated With Brain Atrophy In Secondary Progressive Multiple Sclerosis,” was published in the journal Wellcome…

Certain contrast agents used during magnetic resonance imaging (MRI) may accumulate in specific brain areas and contribute to disease duration and severity in patients with multiple sclerosis (MS), according to a new study published in the Multiple Sclerosis Journal. The study, “Gadopentetate But Not Gadobutrol Accumulates In The…

Promising data from a small Phase 2a clinical trial sponsored by RedHill Biopharma for an antibiotic designed to fight certain infections suggests that adding the drug candidate to interferon treatment reduced relapse rates and brain lesion formation in patients with relapsing forms of multiple sclerosis (MS). This novel treatment approach was based on…

Health Canada has approved Zinbryta (daclizumab) as a treatment for adults with active relapsing-remitting multiple sclerosis (RRMS), Biogen and AbbVie announced. Zinbryta is a long-acting injection therapy, self-administered monthly, for patients who have had an inadequate response to at least two other MS therapies. “ZINBRYTA™ is the first once-monthly, self-administered treatment…

The brain has a system for orchestrating a defense against viral infections, scientists report in a finding that may advance the understanding of disease processes in multiple sclerosis (MS). The newly discovered system is run by brain immune cells called microglia, and researchers will now focus on understanding how these…

A specific type of channel that facilitates calcium flow is needed for normal development of cells that produce a shield, called myelin, around nerve fibers — a finding that could open up new approaches to regenerating the myelin-producing cells (called oligodendrocytes) lost in multiple sclerosis (MS). Researchers now hope to…

This video from Dulci Hill addresses the topic of walking aids. Many multiple sclerosis patients may feel unstable or fatigued when walking and using a cane, wheeled walker or mobility scooter may help to provide stability, aid balance and help you to get around and keep your independence.

Scientists unraveled the 3-D structure of a key receptor linked to inflammation in multiple sclerosis (MS) — the CC chemokine receptor 2 (CCR2) receptor — when it is bound to two inhibitor molecules simultaneously. This potentially important finding, which allows scientists to see how these molecules fit together, could aid in developing better therapeutics that…

Researchers monitoring the decomposition of an abundant brain protein, called myelin basic protein (MBP), discovered that this protein breaks down differently in people with multiple sclerosis (MS) than it does in those without the disease, particularly in two surface regions, and that difference may be the trigger for immune reactions and myelin…

A new study confirmed the involvement of three genetic variants, or mutations, of the interleukin-23A (IL-23A) gene, and one variant of its receptor IL-23R,  in the risk of developing multiple sclerosis (MS) and other related inflammatory nervous disorders, together known as inflammatory demyelinating diseases (IDD). Details of this study, “Characterization of…

Alterations in microorganisms in the brains of multiple sclerosis (MS) patients could contribute to underlying disease mechanisms, including demyelination, according to researchers. The study, “Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis,” was published in the journal Scientific Reports. It is widely recognized that the…

Multiple sclerosis (MS) patients now taking part in a Phase 2b clinical trial testing the efficacy and safety of the antibody GNbAC1 will be invited to continue with treatment for two more years under a planned extension study, the biopharmaceutical companies GeNeuro and Servier recently announced. Several MS therapies rely on the capacity of antibodies to…

The less oxygen that a mouse with multiple sclerosis (MS) has in the gray matter of its brain, the more mental and physical deterioration it is likely to have, a new study suggests. The study confirms previous research indicating a connection between low oxygen levels in a mouse’s gray matter and the development…

European users of Copaxone (glatiramer acetate injection, Teva Pharmaceutical) to treat relapsing forms of multiple sclerosis (RMS) will no longer see a warning that the drug should not be used during pregnancy. A report assessing this change in the drug’s marketing authorization within the European Union — a process known as…

The Consortium of Multiple Sclerosis Centers (CMSC) is inviting researchers and healthcare professionals to submit abstracts to be presented at its 31st Annual Meeting, focusing on developments in multiple sclerosis (MS) research, patient care and treatment outcomes. The 2017 CMSC meeting, organized by the group’s Continuing Professional Education Committee, will take…

In a new and possibly important insight into the workings of the immune system, researchers discovered what it takes for T-cells to start targeting myelin sheets in multiple sclerosis (MS). The findings may also explain why some drugs fail to prevent autoimmunity in MS. The study, “Trans-presentation…